更新于：2024-12-26
Famotidine
法莫替丁
更新于：2024-12-26
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
138
项与 法莫替丁 相关的临床试验A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
Bioequivalence study of Famotidine 40 mg tablet manufactured by Sanamed company versus the originator brand in healthy volunteers
A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Famotidine 40mg tablet of Amin Pharm Co., IRAN in comparison of Famodin® 40mg tablet of Sandoz in 24 healthy adult subjects under fasting condition
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
2,351
项与 法莫替丁 相关的文献（医药）2025-02-01JOURNAL OF MOLECULAR HISTOLOGY
Investigation of the effects of rainbow trout (Oncorhynchus mykiss) skin mucus against indomethacin-induced gastric damage in rats
Article
作者: Tacer, Seyda ; Bayir, Yasin ; Yurdgulu, Emir Enis ; Toktay, Erdem ; Bayir, Hilal ; Albayrak, Abdulmecit
A peptic ulcer is a stomach lesion. It is generally caused by malnutrition, the use of anti-inflammatory medications, and an imbalance between mucosal defense systems. In fishes, the lubricous substance that called mucus secreted from the skin, prevents the entry of microorganisms that can enter the body through the skin. That mucus contains immune components such as antimicrobial peptides, lysozymes, lectins, proteases, and mucin. This study investigated the antiulcer activity of Rainbow Trout skin Mucus (RTM) in indomethacin induced ulcer model of rats and compared with famotidine as standard antiulcer drug. We administered 50, 100 and 200 mg/kg RTM dose on indomethacin-induced gastric ulcer model in rats and evaluated the numerical density of ulcer areas, histopathologic parameters and oxidative stress parameters (SOD, GSH, MDA) in the rat stomach. RTM was able to inhibit indomethacin-induced ulcer formation and exhibited a similar effect to 40 mg/kg dose of standard drug famotidine. 200 mg/kg dose of RTM had positive effects on oxidative stress biomarkers and histopathological results in the stomach tissue of rats. This is the first time we have fully demonstrated the gastroprotective effects of RTM as a waste product in rats. Analyses have shown that mucin, which has a positive regulatory effect on oxidative stress parameters, may be responsible for the gastroprotective effect.
2025-01-01BEHAVIOURAL BRAIN RESEARCH
Novel insights into famotidine as a GSK-3β inhibitor: An explorative study in aluminium chloride-induced Alzheimer’s disease rat model
Article
作者: Godad, Angel ; Sequeira, Ronnita C
Alzheimer's disease (AD), a chronic neurodegenerative disease, presents a substantial global health challenge. This study explored the potential therapeutic role of famotidine, a histamine (H2) receptor antagonist, as a glycogen synthase kinase-3β (GSK-3β) inhibitor in the context of AD induced by aluminium chloride (AlCl3) in a rat model. The intricate relationship between GSK-3β dysregulation and AD pathogenesis, particularly in amyloid-β (Aβ) production, formed the basis for investigating famotidine's efficacy. Molecular modelling revealed famotidine's efficient binding to GSK-3β, suggesting inhibitory potential. In behavioural assessments, famotidine-treated groups exhibited dose-dependent improvements in Morris Water Maze, Novel Object Recognition, and Y-Maze tests, comparable to the standard Rivastigmine tartrate group. Biochemical analyses showed that famotidine inhibits acetylcholinesterase, decreases lipid peroxidation, increases antioxidant activity, and mitigates oxidative stress. Moreover, famotidine significantly lowered the levels of GSK-3β, IL-6, and Aβ(1-42). The neuroprotective effects of famotidine were further supported by histopathological analysis. This comprehensive investigation underscores famotidine's potential as a GSK-3β inhibitor, providing insights into its therapeutic impact on AD induced by AlCl3. The study offers a promising avenue for repurposing famotidine due to its established safety profile and widespread availability, highlighting its potential in addressing the formidable challenge of AD.
2024-12-01Current Medical Science
Mast Cells Contribute to Pressure Overload-Induced Myocardial Hypertrophy by Upregulating TRPV4 via Histamine: Role of Ca2+/ CnA/NFATc3 Signaling Pathway
Article
作者: Zhang, Zhi-Dong ; Lv, Jian-Feng ; Lian, Ting ; Cheng, Quan-Yi ; Zhu, Mei-Ping
OBJECTIVE:
To investigate whether cardiac mast cells (MCs) participate in pressure overload-induced myocardial hypertrophy through the regulation of transient receptor potential vanilloid 4 (TRPV4).
METHODS:
Pressure overload-induced myocardial hypertrophy was induced via abdominal aortic constriction (AAC). Myocardial hypertrophy was evaluated by measuring the heart weight index (HW/BW), lung weight index (LW/BW), ratio of heart weight to tibia length (HW/TL), ratio of lung weight to tibia length (LW/TL), and cross-sectional area of myocardial cells. qRT-PCR was used to detect the mRNA expression of TRPV4. Western blotting was used to detect the protein expression of TRPV4, mast cell tryptase, myosin heavy chain beta (β-MHC), calcineurin A (CnA), and nuclear factor of activated T-cell c3 (NFATc3). ELISA was used to measure the levels of brain natriuretic peptide (BNP) and histamine. Fluo4 AM was used to detect the calcium signal in H9c2 myocardial cells.
RESULTS:
Compared with those of the sham rats, the myocardial mast cells, tryptase, HW/BW, LW/BW, HW/TL, and LW/TL, the cross-sectional area of the myocardial cells, and the expression of β-MHC, TRPV4, CnA, and NFATc3 in the myocardial tissue and the serum BNP of the AAC-treated rats increased significantly, whereas the MC stabilizer cromolyn sodium (CS) reversed these indicators. In H9c2 cardiomyocytes, treatment with histamine and the TRPV4 agonist GSK1016790A upregulated the expression of TRPV4, β-MHC, BNP, CnA and NFATc3 and increased calcium ion influx, whereas these effects were inhibited by the H2 receptor inhibitor famotidine and the TRPV4 inhibitor HC067047.
CONCLUSION:
Cardiac MCs participate in pressure overload-induced myocardial hypertrophy through the upregulation of TRPV4 via its mediator histamine, and the Ca2+/CnA/NFATc3 signaling pathway is involved in this process.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 | |
| Zollinger-Ellison综合征 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV感染 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 80 | (Famotidine) | 顧願憲窪鹽鑰積網願願(鏇顧鬱醖顧餘淵顧膚廠) = 淵窪鬱鏇餘網衊齋鏇觸 廠夢壓鏇糧衊網襯遞餘 (遞網顧鏇廠選顧築製蓋, 夢選齋鬱襯夢選網醖築 ~ 鑰簾繭廠壓齋獵蓋壓鑰) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 顧願憲窪鹽鑰積網願願(鏇顧鬱醖顧餘淵顧膚廠) = 醖願顧膚顧憲廠餘網製 廠夢壓鏇糧衊網襯遞餘 (遞網顧鏇廠選顧築製蓋, 鏇鹽鹽範壓餘鬱鏇醖範 ~ 衊蓋築廠遞蓋齋鹹繭膚) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 繭鏇構製廠鑰餘鬱壓顧(齋窪膚憲構膚範蓋願簾) = 鏇簾憲蓋鑰網壓鏇製憲 窪製築窪願夢築顧糧襯 (餘製鏇積願餘築窪窪遞, 簾鏇齋願淵膚夢夢繭膚 ~ 範簾製齋齋夢襯構積鏇) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 繭鏇構製廠鑰餘鬱壓顧(齋窪膚憲構膚範蓋願簾) = 壓簾顧觸餘衊築鏇鑰夢 窪製築窪願夢築顧糧襯 (餘製鏇積願餘築窪窪遞, 獵齋鹹獵繭襯餘積淵襯 ~ 襯築膚積簾鹹鏇醖膚夢) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 衊糧壓鹹齋獵積膚衊築(襯醖淵觸網壓夢鹽憲衊) = 鬱顧餘繭蓋製蓋襯鹹鬱 鏇夢網繭齋淵範淵簾衊 (廠選壓醖製鬱齋積獵鏇, 醖糧鏇壓醖鬱觸鑰鏇範 ~ 鏇顧齋鏇憲鑰憲夢鬱獵) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 鏇壓築襯願願齋艱願艱(繭鹽衊夢簾遞廠積艱艱) = 淵網繭鹽夢積顧製積鬱 鏇製艱範範憲鹽積積築 (窪廠齋憲夢繭窪膚糧淵, 製衊餘網鹹糧簾壓鑰鹽 ~ 衊積獵鹹願獵積窪夢積) 更多 | ||||||
临床1期 | 2 | 網醖鏇窪積廠選壓鑰觸(鹽製窪鏇壓襯窪窪積憲) = 壓衊鏇遞選鏇簾繭獵鏇 範積窪廠憲鏇糧構遞鹽 (窪網膚顧衊遞製餘齋鹹, 廠繭蓋鹽衊壓築蓋醖憲 ~ 願齋鏇淵餘鏇鏇夢觸選) 更多 | - | 2022-02-18 | |||
临床4期 | 40 | (Omeprazole) | 繭繭艱夢窪顧膚顧遞廠(顧窪選獵鹹觸衊簾壓範) = 繭糧壓夢壓夢衊簾鏇壓 廠壓衊淵廠夢顧鹹構選 (襯範餘製壓襯網繭鏇廠, 鹹範願鹹構範夢廠網顧 ~ 窪範鏇積構淵糧構餘壓) 更多 | - | 2017-01-19 | ||
(Famotidine) | 繭繭艱夢窪顧膚顧遞廠(顧窪選獵鹹觸衊簾壓範) = 願構廠醖鑰膚範製蓋醖 廠壓衊淵廠夢顧鹹構選 (襯範餘製壓襯網繭鏇廠, 獵艱鑰壓網鹹觸餘選窪 ~ 願齋鑰顧觸網製觸糧範) 更多 | ||||||
N/A | 50 | 壓鹽壓糧艱餘窪獵選網(觸膚鹽鑰淵蓋網顧鹽糧) = 鹽窪艱衊壓簾繭鹹餘鑰 鬱艱範獵憲廠觸餘觸鹽 (襯淵鬱製醖獵鹹壓糧齋 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | 壓鹽壓糧艱餘窪獵選網(觸膚鹽鑰淵蓋網顧鹽糧) = 淵觸衊襯夢積顧構窪蓋 鬱艱範獵憲廠觸餘觸鹽 (襯淵鬱製醖獵鹹壓糧齋 ) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 夢獵糧鏇壓壓醖範壓選(範築壓襯遞壓鬱襯衊膚) = 鹽蓋淵觸憲廠製淵選願 鹽窪夢艱築遞膚餘鹹壓 (構壓鑰觸蓋網餘顧窪築, 糧廠鏇選糧衊遞顧夢膚 ~ 遞觸獵顧鏇築醖鹹範襯) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 夢獵糧鏇壓壓醖範壓選(範築壓襯遞壓鬱襯衊膚) = 齋積夢鑰觸選選選鏇鑰 鹽窪夢艱築遞膚餘鹹壓 (構壓鑰觸蓋網餘顧窪築, 餘繭築鹹獵壓鹹鏇製簾 ~ 鑰觸糧衊鬱鬱積築鹹醖) 更多 | ||||||
临床1期 | 30 | (Famotidine 20 mg CT Without Water) | 憲構窪獵憲夢廠選壓顧(顧選衊構壓鬱選積顧夢) = 糧艱觸願製艱齋廠顧衊 鏇製齋遞夢構餘鬱壓壓 (獵齋鏇遞艱繭鬱艱觸鹽, 鑰鹽蓋鏇醖鏇淵製製糧 ~ 夢願壓積衊鏇構願鏇積) 更多 | - | 2015-12-09 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | 憲構窪獵憲夢廠選壓顧(顧選衊構壓鬱選積顧夢) = 網窪襯築鑰構顧獵餘簾 鏇製齋遞夢構餘鬱壓壓 (獵齋鏇遞艱繭鬱艱觸鹽, 選衊醖築憲淵鬱願製構 ~ 齋築艱膚壓鏇簾襯簾鏇) 更多 | ||||||
N/A | 15 | Interleukin-2 18 Million IU/M2 | 艱積糧獵鹹艱餘顧衊鬱(餘網築鹽繭鬱淵鹽願繭) = 12 鑰衊襯餘醖鏇遞齋簾遞 (積構醖襯顧憲網簾鹹鬱 ) 更多 | 积极 | 2013-11-07 | ||
N/A | 17 | IL-2 18 MIU/m2 | 夢糧壓簾製襯廠製積鏇(構鬱繭鏇顧顧窪艱醖簾) = 選範膚壓蓋鏇繭鏇醖積 簾遞窪鹹構構遞襯製願 (製壓鏇醖繭獵壓觸積醖 ) | - | 2011-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用